Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Background The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 23, 2017
|
| In: |
The lancet. Oncology
Year: 2017, Jahrgang: 18, Heft: 10, Pages: 1327-1337 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(17)30578-8 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S1470-2045(17)30578-8 Verlag, Volltext: https://linkinghub.elsevier.com/retrieve/pii/S1470204517305788 
|
| Verfasserangaben: | Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, Douglas Joshua, Wee-Joo Chng, Albert Oriol, Robert Z Orlowski, Heinz Ludwig, Thierry Facon, Roman Hajek, Katja Weisel, Vania Hungria, Leonard Minuk, Shibao Feng, Anita Zahlten-Kumeli, Amy S Kimball, Philippe Moreau |
| Zusammenfassung: | Background The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups. |
|---|---|
| Beschreibung: | Gesehen am 28.11.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(17)30578-8 |